Takeda’s LIVTENCITY (Maribavir) Approved by U.S. FDA as the First and Only Treatment of Post-Transplant Cytomegalovirus (CMV), that is Resistant to other Antiviral Drugs.
SYNOPSIS: Takeda announced that U.S. FDA Approved LIVTENCITY (Maribavir) as the First and Only Treatment for People Ages 12 or older and…